×
VAXART, INC Common Stock Net 2010-2024 | VXRT
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
VAXART, INC common stock net from 2010 to 2024. Common stock net can be defined as the value of common equity ownership.
View More
VAXART, INC Common Stock Net 2010-2024 | VXRT
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
VAXART, INC common stock net from 2010 to 2024. Common stock net can be defined as the value of common equity ownership.
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$88.3B
Takeda Pharmaceutical (TAK)
$46.3B
Merck (MKGAF)
$22.8B
Astellas Pharma (ALPMY)
$21.5B
Sandoz Group AG (SDZNY)
$18B
United Therapeutics (UTHR)
$16B
Summit Therapeutics (SMMT)
$15.1B
Shionogi (SGIOY)
$13.2B
Neurocrine Biosciences (NBIX)
$11.6B
Catalent (CTLT)
$10.9B
Orion OYJ (ORINY)
$8B
Revolution Medicines (RVMD)
$7.4B
Jazz Pharmaceuticals (JAZZ)
$6.9B
Ionis Pharmaceuticals (IONS)
$6B
Hikma Pharmaceuticals Plc (HKMPF)
$5.7B
Madrigal Pharmaceuticals (MDGL)
$4.6B
Corcept Therapeutics (CORT)
$4.6B
Crinetics Pharmaceuticals (CRNX)
$4.1B
Dyne Therapeutics (DYN)
$3.4B
PTC Therapeutics (PTCT)
$2.9B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.5B
Arrowhead Pharmaceuticals (ARWR)
$2.4B
Catalyst Pharmaceuticals (CPRX)
$2.3B
Recursion Pharmaceuticals (RXRX)
$2B
Soleno Therapeutics (SLNO)
$1.9B
Centessa Pharmaceuticals (CNTA)
$1.8B
Xencor (XNCR)
$1.6B
BioCryst Pharmaceuticals (BCRX)
$1.6B
Ardelyx (ARDX)
$1.6B
Harrow (HROW)
$1.6B